tiprankstipranks
COMPASS Pathways (DE:5Y6)
MUNICH:5Y6

COMPASS Pathways Stock Price & Analysis

0 Followers

5Y6 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€11.85
Volume0.00
Average Volume (3M)209.00
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
P/E RatioN/A
Beta2.31
Next EarningsNov 17, 2022
EPS Estimate-€0.68
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares OutstandingN/A
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume209
P/B RatioN/A
P/S RatioN/A
P/CF RatioN/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside409.87% Upside
Rating ConsensusStrong Buy
AlphaN/A
Number of Analyst Covering4


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

5Y6 FAQ

What was COMPASS Pathways’s price range in the past 12 months?
Currently, no data Available
What is COMPASS Pathways’s market cap?
Currently, no data Available
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Nov 17, 2022 which is in 49 days.
    How were COMPASS Pathways’s earnings last quarter?
    COMPASS Pathways released its earnings results on Aug 04, 2022. The company reported -€0.523 earnings per share for the quarter, beating the consensus estimate of -€0.636 by €0.113.
      Is COMPASS Pathways overvalued?
      According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does COMPASS Pathways pay dividends?
        COMPASS Pathways does not currently pay dividends.
        What is COMPASS Pathways’s EPS estimate?
        COMPASS Pathways’s EPS estimate is -€0.68.
          How many shares outstanding does COMPASS Pathways have?
          Currently, no data Available
          What happened to COMPASS Pathways’s price movement after its last earnings report?
          COMPASS Pathways reported an EPS of -€0.523 in its last earnings report, beating expectations of -€0.636. Following the earnings report the stock price went down -3.135%.
            Which hedge fund is a major shareholder of COMPASS Pathways?
            Among the largest hedge funds holding COMPASS Pathways’s share is Saba Capital Management. It holds COMPASS Pathways’s shares valued at 4M.

              ---

              COMPASS Pathways Stock Analysis

              Smart ScoreOutperform
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              9

              Analyst Consensus

              Strong Buy
              Average Price Target: €60.42

              Blogger Sentiment

              Bullish
              DE:5Y6 Sentiment 83% Sector Average 70%

              Insider Transactions

              N/A
              Currently Not Enough Data Available

              News Sentiment

              Neutral
              Bullish 50% Bearish 50%

              Technicals

              SMA
              Positive
              20 days / 200 days
              Momentum
              -62.55%
              12-Months-Change

              Fundamentals

              Return on Equity
              -30.21%
              Trailing 12-Months
              Asset Growth
              -28.80%
              Trailing 12-Months
              The COMPASS Pathways Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              COMPASS Pathways

              Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Immunocore Holdings
              Myovant Sciences
              Exscientia Plc
              Bicycle Therapeutics

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis